Page 42 - Read Online

Page 10 of 14 Moriguchi et al. Hepatoma Res 2019;5:43 I http://dx.doi.org/10.20517/2394-5079.2019.20

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
3. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-85.
4. Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C
hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol 2015;50:350-60.
5. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, et al. Association of nonalcoholic fatty liver disease (NAFLD) with
hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30.
6. Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a
review of human studies. Clin J Gastroenterol 2015;8:1-9.
7. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and
obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27.
8. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis
of 1698 population-based measurement studies with 19·2 million participants. Lancet 2016;387:1377-96.
9. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology
2014;59:1174-97.
10. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-64.
11. Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease. Clin Liver Dis 2016;20:387-401.
12. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology
2011;140:124-31.
13. Younossi ZM, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors
and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
14. Li J, Zou B, Yeo YH, Feng Y, Xie X, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019:
a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389-98.
15. Seydel GS, Kucukoglu O, Altinbas A, Demir OO, Yilmaz S, et al. Economic growth leads to increase of obesity and associated
hepatocellular carcinoma in developing countries. Ann Hepatol 2016;15:662-72.
16. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and
pathological severity. Gastroenterology 1999;116:1413-9.
17. Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence,
severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:198-210.
18. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular
carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014;147:143-51.
19. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gastroenterology 2017;153:996-1005.
20. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, et al. Global patterns of hepatocellular carcinoma management from
diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-66.
21. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.
22. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic
assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
23. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty
liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol
2011;46:1230-7.
24. Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver
disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007;243:422-30.
25. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a
multidisciplinary team. J Hepatol 2014;60:110-7.
26. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, et al.; HCC-NAFLD Italian Study Group. Clinical patterns of
hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.
27. Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, et al. Comparing clinical presentations, treatments and outcomes of
hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81.
28. Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, et al. Prospective study of hepatocellular carcinoma in nonalcoholic
steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 2010;45:960-7.
29. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res
2012;4:1-4.
30. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, et al; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of
Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol
2011;9:428-33.